The first set of immunogenicity data from the first trial of a potential vaccine to treat the coronavirus that causes COVID-19 could come as early as June, according to Evercore analyst Umer Ruffat. The National Institutes of Health is funding the trial of a vaccine developed by Moderna Inc. (MRNA) that kicked off Monday, and is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle. "Management said they expect to dose first patients very shortly (they've screened a bunch already)," Raffat wrote in a Monday note to clients. Moderna management told Evercore that it could have 10 million doses ready by summer. "Moderna used experience from other trials of its vaccines to inform these doses (because other vaccines have shown immunogenicity at doses as low as 10 mcg)," said the analyst. Moderna shares rose 27% Monday.
-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
March 16, 2020 14:54 ET (18:54 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.